Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Taekyu Lee, Plamen P. Christov, Subrata Shaw, James C. Tarr, Bin Zhao, Nagarathanam Veerasamy, Kyu Ok Jeon, Jonathan J. Mills, Zhiguo Bian, John L. Sensintaffar, Allison L. Arnold, Stuart A. Fogarty, Evan Perry, Haley E. Ramsey, Rebecca S. Cook, Melinda Hollingshead, Myrtle Davis Millin, Kyung Min Lee, Brian Koss, Amit BudhrajaJoseph T. Opferman, Kwangho Kim, Carlos L. Arteaga, William J. Moore, Edward T. Olejniczak, Michael R. Savona, Stephen W. Fesik

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Overexpression of myeloid cell leukemia-1 (Mcl-1) in cancers correlates with high tumor grade and poor survival. Additionally, Mcl-1 drives intrinsic and acquired resistance to many cancer therapeutics, including B cell lymphoma 2 family inhibitors, proteasome inhibitors, and antitubulins. Therefore, Mcl-1 inhibition could serve as a strategy to target cancers that require Mcl-1 to evade apoptosis. Herein, we describe the use of structure-based design to discover a novel compound (42) that robustly and specifically inhibits Mcl-1 in cell culture and animal xenograft models. Compound 42 binds to Mcl-1 with picomolar affinity and inhibited growth of Mcl-1-dependent tumor cell lines in the nanomolar range. Compound 42 also inhibited the growth of hematological and triple negative breast cancer xenografts at well-tolerated doses. These findings highlight the use of structure-based design to identify small molecule Mcl-1 inhibitors and support the use of 42 as a potential treatment strategy to block Mcl-1 activity and induce apoptosis in Mcl-1-dependent cancers.

Original languageEnglish (US)
Pages (from-to)3971-3988
Number of pages18
JournalJournal of Medicinal Chemistry
Volume62
Issue number8
DOIs
StatePublished - Apr 25 2019
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer'. Together they form a unique fingerprint.

  • Cite this

    Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K. M., Koss, B., ... Fesik, S. W. (2019). Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of Medicinal Chemistry, 62(8), 3971-3988. https://doi.org/10.1021/acs.jmedchem.8b01991